Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.

2.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

3.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.

J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14.

PMID:
21674569
4.

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J.

Eur J Neurosci. 2007 Aug;26(4):843-51. Epub 2007 Aug 2.

PMID:
17672854
5.

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.

Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Mol Pharmacol. 2011 Jun;79(6):964-73. doi: 10.1124/mol.111.071290. Epub 2011 Feb 24.

6.

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V.

Br J Pharmacol. 2011 Feb;162(3):584-96. doi: 10.1111/j.1476-5381.2010.01063.x.

7.

The multiplicity of action of cannabinoids: implications for treating neurodegeneration.

Gowran A, Noonan J, Campbell VA.

CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28. Review.

PMID:
20875047
8.

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z.

J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12.

9.

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D.

Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review.

10.

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. Review.

PMID:
22280340
11.

Molecular Targets of Cannabidiol in Neurological Disorders.

Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ.

Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3. Review.

12.

Endocannabinoid system dysfunction in mood and related disorders.

Ashton CH, Moore PB.

Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9. Review.

PMID:
21916860
13.

Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.

Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J.

Neuropharmacology. 2013 Aug;71:282-91. doi: 10.1016/j.neuropharm.2013.03.027. Epub 2013 Apr 12.

PMID:
23587650
14.

Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.

Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, Rausch WD.

Phytomedicine. 2012 Jun 15;19(8-9):819-24. doi: 10.1016/j.phymed.2012.04.002. Epub 2012 May 7.

PMID:
22571976
15.

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review.

16.

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.

Kozela E, Juknat A, Vogel Z.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1669. doi: 10.3390/ijms18081669. Review.

17.

Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.

McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA.

Mol Pharmacol. 2008 Feb;73(2):441-50. Epub 2007 Oct 26.

18.

The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors.

Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J.

Neurobiol Dis. 2010 Feb;37(2):434-40. doi: 10.1016/j.nbd.2009.10.023. Epub 2009 Nov 6.

PMID:
19900555
19.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

20.

Regulation of nausea and vomiting by cannabinoids.

Parker LA, Rock EM, Limebeer CL.

Br J Pharmacol. 2011 Aug;163(7):1411-22. doi: 10.1111/j.1476-5381.2010.01176.x. Review.

Supplemental Content

Support Center